Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
22
PRQR Quote, Financials, Valuation and Earnings
Last price:
$1.62
Seasonality move
:
-10.69%
Day range:
$1.53 - $1.60
52-week range:
$1.07 - $3.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.62x
P/B ratio:
2.50x
Volume:
279.9K
Avg. volume:
386.3K
1-year change:
-33.75%
Market cap:
$167.5M
Revenue:
$20.4M
EPS (TTM):
-$0.46
Analysts' Opinion
-
Consensus RatingProQR Therapeutics NV has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.88, ProQR Therapeutics NV has an estimated upside of 458.18% from its current price of $1.59.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $1.59.
Fair Value
-
According to the consensus of 7 analysts, ProQR Therapeutics NV has 458.18% upside to fair value with a price target of $8.88 per share.
PRQR vs. S&P 500
-
Over the past 5 trading days, ProQR Therapeutics NV has overperformed the S&P 500 by 8.17% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ProQR Therapeutics NV does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ProQR Therapeutics NV revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter ProQR Therapeutics NV reported revenues of $3.4M.
Earnings Growth
-
ProQR Therapeutics NV earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter ProQR Therapeutics NV reported earnings per share of -$0.12.
Enterprise value:
59.1M
EV / Invested capital:
--
Price / LTM sales:
9.62x
EV / EBIT:
--
EV / Revenue:
3.46x
PEG ratio (5yr expected):
-0.08x
EV / Free cash flow:
-1.01x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$14.1M
Return On Assets:
-30.87%
Net Income Margin (TTM):
-276.92%
Return On Equity:
-67.34%
Return On Invested Capital:
-54.22%
Operating Margin:
-392.68%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $4.2M | $19.4M | $17M | $4.2M | $3.4M | |
| Gross Profit | $75.4K | $13.6M | $14.1M | $3.5M | $2.6M | |
| Operating Income | -$41M | -$32.7M | -$49.8M | -$9.7M | -$13.2M | |
| EBITDA | -$38.3M | -$29.6M | -$46.8M | -$9M | -$12.4M | |
| Diluted EPS | -$0.48 | -$0.32 | -$0.46 | -$0.11 | -$0.12 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $205.2M | $102M | $132M | $103.1M | $130.8M | |
| Total Assets | $226.4M | $119.3M | $150.4M | $119.3M | $146.1M | |
| Current Liabilities | $40.2M | $26.4M | $28.2M | $44.2M | $38.9M | |
| Total Liabilities | $78M | $56M | $101.3M | $91.4M | $79.1M | |
| Total Equity | $148.4M | $63.2M | $49.1M | $27.9M | $67.1M | |
| Total Debt | $41.5M | $21.8M | $22.5M | $17.6M | $17.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $10.4M | -$35.8M | -$55.2M | -$6.7M | -$15.3M | |
| Cash From Investing | -$774.8K | $4M | -$3.5M | $18M | -$208.9K | |
| Cash From Financing | $12.2M | -$2.4M | $74.8M | -$513.1K | -$546.8K | |
| Free Cash Flow | $9.6M | -$40.3M | -$58.7M | -$7M | -$15.5M | |
PRQR
Sector
Market Cap
$167.5M
$25.8M
Price % of 52-Week High
51.29%
50.24%
Dividend Yield
0%
0%
Shareholder Yield
-33.95%
-1.64%
1-Year Price Total Return
-33.75%
-18.88%
Beta (5-Year)
0.200
0.496
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.49
200-day SMA
Sell
Level
$2.06
Bollinger Bands (100)
Sell
Level
1.65 - 2.51
Chaikin Money Flow
Buy
Level
144.6K
20-day SMA
Buy
Level
$1.50
Relative Strength Index (RSI14)
Buy
Level
51.19
ADX Line
Buy
Level
33.67
Williams %R
Sell
Level
-3.7037
50-day SMA
Sell
Level
$1.77
MACD (12, 26)
Buy
Level
0.42
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
670.4K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.2256)
Sell
CA Score
(Annual)
Level (-1.7082)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (1.2928)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.
Stock Forecast FAQ
In the current month, PRQR has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PRQR average analyst price target in the past 3 months is $8.88.
-
Where Will ProQR Therapeutics NV Stock Be In 1 Year?
According to analysts, the consensus estimate is that ProQR Therapeutics NV share price will rise to $8.88 per share over the next 12 months.
-
What Do Analysts Say About ProQR Therapeutics NV?
Analysts are divided on their view about ProQR Therapeutics NV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ProQR Therapeutics NV is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is ProQR Therapeutics NV's Price Target?
The price target for ProQR Therapeutics NV over the next 1-year time period is forecast to be $8.88 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PRQR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ProQR Therapeutics NV is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PRQR?
You can purchase shares of ProQR Therapeutics NV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ProQR Therapeutics NV shares.
-
What Is The ProQR Therapeutics NV Share Price Today?
ProQR Therapeutics NV was last trading at $1.62 per share. This represents the most recent stock quote for ProQR Therapeutics NV. Yesterday, ProQR Therapeutics NV closed at $1.59 per share.
-
How To Buy ProQR Therapeutics NV Stock Online?
In order to purchase ProQR Therapeutics NV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get PRQR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PRQR
Sector
P/E ratio
--
23.44x
PEG ratio
-0.08x
-0.01x
P/B ratio
2.50x
1.81x
Price / LTM sales
9.62x
1.56x
Growth Metrics
PRQR
Sector
Revenue growth
-20.23%
3.27%
Earnings growth
-12.02%
9.66%
Revenue (5-year growth)
--
6.43%
Earnings forecast
-$0.17
-$0.20
Profitability
PRQR
Sector
Profitability FY 2024
$17.5M
$2.3M
Return on invested capital
-54.22%
-33.49%
Return on assets
-30.87%
-29.74%
Return on equity
-67.34%
-39.33%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
12
Estimated Next Earnings Date
Feb
5
Balance Sheet
PRQR
Sector
Total cash
$125.6M
$24.2M
Short term investments
--
$23.8M
Total assets
$173.9M
$71.1M
Long term debt
$17.1M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 14.29% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 7.51% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 5.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
